OraSure公司非处方类HIV快速检测试剂盒获FDA批准上市

2012-07-23 jewell 生物谷

7月3日,美国OraSure科技公司宣布,FDA批准其OraQuick In-Home HIV Test(家庭式HIV快速诊断)试剂盒作为非处方药(OTC)上市,这是在美国获批的第一例也是现有唯一一个OTC类快速HIV检测试剂盒。 OraQuick In-Home HIV Test可检测HIV-1及HIV-2抗体,它通过口腔拭子便可在20分钟内给出一个不为人知的家庭测试结果。它是OraSure推

7月3日,美国OraSure科技公司宣布,FDA批准其OraQuick In-Home HIV Test(家庭式HIV快速诊断)试剂盒作为非处方药(OTC)上市,这是在美国获批的第一例也是现有唯一一个OTC类快速HIV检测试剂盒。

OraQuick In-Home HIV Test可检测HIV-1及HIV-2抗体,它通过口腔拭子便可在20分钟内给出一个不为人知的家庭测试结果。它是OraSure推出的OraQuick ADVANCE HIV 1/2 Antibody Test试剂盒的OTC版本。

OraQuick In-Home HIV Test也是第一个由FDA批准上市的用于传染性疾病快速诊断的OTC类检测试剂盒。

“OraQuick In-Home HIV Test的获准代表了HIV检测的一个重大突破,”OraSure公司总裁兼CEO Douglas Michels表示。“有史以来第一次,人们通过一个家用的口试检测试剂盒在家里就能了解自己的HIV感染情况,并根据结果获得所需护理...”

3日下午,OraSure公司股票在纳斯达克(Nasdaq)上涨了51美分即4.44%,达12.01美元。(生物谷Bioon.com)

编译自FDA Okays OraSure's OraQuick In-Home HIV Test

>>相关阅读

罗氏新型HIV病毒载量检测方法获FDA批准

OraSure公司家庭HIV检测试剂盒获FDA专家顾问小组一致肯定

Orasure的Hiv-1/2快速测试仪获得批准

Lancet Infect Dis:与传统血液检测方法相比 口腔HIV诊断敏感性要低2

迅速的唾液HIV检测将成为艾滋病检测新标准

版权声明:
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于williamhill asia 医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章,或“williamhill asia 号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系,williamhill asia 将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1934626, encodeId=f063193462658, content=<a href='/topic/show?id=325762560c5' target=_blank style='color:#2F92EE;'>#检测试剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62560, encryptionId=325762560c5, topicName=检测试剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Sat Jan 05 22:56:00 CST 2013, time=2013-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839167, encodeId=6da0183916ef8, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Mon Nov 12 13:56:00 CST 2012, time=2012-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992609, encodeId=e8641992609af, content=<a href='/topic/show?id=b9f562561a1' target=_blank style='color:#2F92EE;'>#检测试剂盒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62561, encryptionId=b9f562561a1, topicName=检测试剂盒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Sun Nov 11 05:56:00 CST 2012, time=2012-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991052, encodeId=939819910520e, content=<a href='/topic/show?id=69bd91e371a' target=_blank style='color:#2F92EE;'>#试剂盒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91737, encryptionId=69bd91e371a, topicName=试剂盒)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Mon Aug 13 23:56:00 CST 2012, time=2012-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1819194, encodeId=fa67181919417, content=<a href='/topic/show?id=0805993615a' target=_blank style='color:#2F92EE;'>#非处方#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99361, encryptionId=0805993615a, topicName=非处方)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f98e185, createdName=psybestwish, createdTime=Wed Oct 03 12:56:00 CST 2012, time=2012-10-03, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1934626, encodeId=f063193462658, content=<a href='/topic/show?id=325762560c5' target=_blank style='color:#2F92EE;'>#检测试剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62560, encryptionId=325762560c5, topicName=检测试剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Sat Jan 05 22:56:00 CST 2013, time=2013-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839167, encodeId=6da0183916ef8, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Mon Nov 12 13:56:00 CST 2012, time=2012-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992609, encodeId=e8641992609af, content=<a href='/topic/show?id=b9f562561a1' target=_blank style='color:#2F92EE;'>#检测试剂盒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62561, encryptionId=b9f562561a1, topicName=检测试剂盒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Sun Nov 11 05:56:00 CST 2012, time=2012-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991052, encodeId=939819910520e, content=<a href='/topic/show?id=69bd91e371a' target=_blank style='color:#2F92EE;'>#试剂盒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91737, encryptionId=69bd91e371a, topicName=试剂盒)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Mon Aug 13 23:56:00 CST 2012, time=2012-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1819194, encodeId=fa67181919417, content=<a href='/topic/show?id=0805993615a' target=_blank style='color:#2F92EE;'>#非处方#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99361, encryptionId=0805993615a, topicName=非处方)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f98e185, createdName=psybestwish, createdTime=Wed Oct 03 12:56:00 CST 2012, time=2012-10-03, status=1, ipAttribution=)]
    2012-11-12 bugit
  3. [GetPortalCommentsPageByObjectIdResponse(id=1934626, encodeId=f063193462658, content=<a href='/topic/show?id=325762560c5' target=_blank style='color:#2F92EE;'>#检测试剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62560, encryptionId=325762560c5, topicName=检测试剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Sat Jan 05 22:56:00 CST 2013, time=2013-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839167, encodeId=6da0183916ef8, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Mon Nov 12 13:56:00 CST 2012, time=2012-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992609, encodeId=e8641992609af, content=<a href='/topic/show?id=b9f562561a1' target=_blank style='color:#2F92EE;'>#检测试剂盒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62561, encryptionId=b9f562561a1, topicName=检测试剂盒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Sun Nov 11 05:56:00 CST 2012, time=2012-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991052, encodeId=939819910520e, content=<a href='/topic/show?id=69bd91e371a' target=_blank style='color:#2F92EE;'>#试剂盒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91737, encryptionId=69bd91e371a, topicName=试剂盒)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Mon Aug 13 23:56:00 CST 2012, time=2012-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1819194, encodeId=fa67181919417, content=<a href='/topic/show?id=0805993615a' target=_blank style='color:#2F92EE;'>#非处方#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99361, encryptionId=0805993615a, topicName=非处方)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f98e185, createdName=psybestwish, createdTime=Wed Oct 03 12:56:00 CST 2012, time=2012-10-03, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1934626, encodeId=f063193462658, content=<a href='/topic/show?id=325762560c5' target=_blank style='color:#2F92EE;'>#检测试剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62560, encryptionId=325762560c5, topicName=检测试剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Sat Jan 05 22:56:00 CST 2013, time=2013-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839167, encodeId=6da0183916ef8, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Mon Nov 12 13:56:00 CST 2012, time=2012-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992609, encodeId=e8641992609af, content=<a href='/topic/show?id=b9f562561a1' target=_blank style='color:#2F92EE;'>#检测试剂盒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62561, encryptionId=b9f562561a1, topicName=检测试剂盒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Sun Nov 11 05:56:00 CST 2012, time=2012-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991052, encodeId=939819910520e, content=<a href='/topic/show?id=69bd91e371a' target=_blank style='color:#2F92EE;'>#试剂盒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91737, encryptionId=69bd91e371a, topicName=试剂盒)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Mon Aug 13 23:56:00 CST 2012, time=2012-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1819194, encodeId=fa67181919417, content=<a href='/topic/show?id=0805993615a' target=_blank style='color:#2F92EE;'>#非处方#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99361, encryptionId=0805993615a, topicName=非处方)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f98e185, createdName=psybestwish, createdTime=Wed Oct 03 12:56:00 CST 2012, time=2012-10-03, status=1, ipAttribution=)]
    2012-08-13 tastas
  5. [GetPortalCommentsPageByObjectIdResponse(id=1934626, encodeId=f063193462658, content=<a href='/topic/show?id=325762560c5' target=_blank style='color:#2F92EE;'>#检测试剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62560, encryptionId=325762560c5, topicName=检测试剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Sat Jan 05 22:56:00 CST 2013, time=2013-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839167, encodeId=6da0183916ef8, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Mon Nov 12 13:56:00 CST 2012, time=2012-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992609, encodeId=e8641992609af, content=<a href='/topic/show?id=b9f562561a1' target=_blank style='color:#2F92EE;'>#检测试剂盒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62561, encryptionId=b9f562561a1, topicName=检测试剂盒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Sun Nov 11 05:56:00 CST 2012, time=2012-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991052, encodeId=939819910520e, content=<a href='/topic/show?id=69bd91e371a' target=_blank style='color:#2F92EE;'>#试剂盒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91737, encryptionId=69bd91e371a, topicName=试剂盒)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Mon Aug 13 23:56:00 CST 2012, time=2012-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1819194, encodeId=fa67181919417, content=<a href='/topic/show?id=0805993615a' target=_blank style='color:#2F92EE;'>#非处方#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99361, encryptionId=0805993615a, topicName=非处方)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f98e185, createdName=psybestwish, createdTime=Wed Oct 03 12:56:00 CST 2012, time=2012-10-03, status=1, ipAttribution=)]

相关威廉亚洲官网

Ariad白血病药物ponatinib在PACE试验中取得积极数据

2012年6月4日,Ariad制药公司的实验性白血病药物ponatinib在一项名为PACE的关键性临床试验中取得积极数据。Ariad公司称,计划在今年第三季度向FDA提交监管申请。 该项研究,已提交至ASCO会议。研究发现,约54%的处于慢性期的慢性髓性白血病(CML)患者对ponatinib产生了主要反应(major response),这意味着,这些患者的骨髓,至少2/3是正常的。这些患者

Onyx公司Kyprolis获FDA肿瘤药物咨询委员会支持

6月20日,Onyx制药公司宣布,FDA肿瘤药物咨询委员会(ODAC)经过效益风险评估,以11:0投票结果决定,支持Kyprolis(Carfilzomib)用于治疗复发/难治性多发性骨髓瘤患者,这类患者此前至少经过包括蛋白酶抑制剂及免疫调节剂的两种疗法。 Onyx称,Kyprolis用于多发性骨髓瘤的研发横跨多种治疗方法。 根据处方药使用者费用法案(Prescription Drug Use

德国Medigene发布RhuDex临床配方试验积极性结果

6月21日,德国生物技术公司Medigene AG宣布,RhuDex临床配方试验获积极性结果,公司将继续开展RhuDex优化口服配方用于治疗自身免疫性疾病的进一步临床研究。 此研究的目的在于建立适于治疗慢性疾病的活性物质优化口服配方。Medigene称,临床试验达到了所有终末点。基于其试验结果,RhuDex可以Gelucire为载体的配方形式给药。 Medigene指出,公司计划于在2012年

2012年5月FDA批准新药概况

2012年5月,FDA批出新分子实体药品1个,新剂型药品2个,新复方剂型药品1个。新分子实体药品为治疗罕见遗传疾病——戈谢病的ELELYSO。新剂型药品分别有他扎罗汀泡沫剂和异维甲酸胶囊。新复方剂型药品为治疗季节性过敏性鼻炎复方制剂(氮卓斯汀+丙酸氟替卡松)。 表:2012年5月FDA批准新药 商品名 通用名(中文) 公司 规格 剂型

葛兰素史克两新药证实可延长皮肤癌患者生命

两种针对黑素瘤皮肤癌的新药物取得初步试验结果。相比传统化学疗法,新药可有效阻止或延缓癌细胞扩散,延长患者生命。 这两种靶向药物名为Dabrafenib和Trametinib,由英国葛兰素史克公司研制,已分别结束初步临床试验,与传统化疗作比对。 研制方3日在美国临床肿瘤学会芝加哥会议上发布临床试验结果。 322名黑素瘤皮肤癌晚期患者参与Trametinib项目试验,其中214人使用Tramet

杨森启动ADX71149在重度抑郁症患者的II期临床试验

6月5日,瑞士制药公司Addex宣布,杨森制药(Janssen)子公司杨森研发(Janssen R & D)已经启动了ADX71149用于治疗伴有焦虑症状的重度抑郁症的II期临床试验。 ADX71149由Addex与Janssen共同研发,是代谢型谷氨酸受体2(mGluR2)的正向别构调节剂(PAM)。同时,另有ADX71149用于治疗精神分裂症阳性与阴性症状的II期临床试验正在进行。